{"id":26283,"date":"2025-06-30T11:54:18","date_gmt":"2025-06-30T04:54:18","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=26283"},"modified":"2025-06-30T11:54:18","modified_gmt":"2025-06-30T04:54:18","slug":"innovent-biologics-showcases-dual-innovations-at-oncology-rd-day-pioneering-the-future-of-cancer-treatment-with-next-generation-io-and-adc-platforms","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=26283","title":{"rendered":"Innovent Biologics Showcases “Dual Innovations” at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms"},"content":{"rendered":"

SAN FRANCISCO<\/span> and SUZHOU, China<\/span><\/span>, June 30, 2025<\/span><\/span> \/PRNewswire\/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, held its Oncology R&D Day, unveiling its forward-looking strategy centered on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies. This strategic focus aims to redefine the standards of cancer treatment and propel Innovent toward becoming a global, premier biopharmaceutical leader. The event drew over 500 participants, including leading oncology key opinion leaders (KOLs), principal investigators, analysts, and global investors, signaling strong engagement with Innovent’s transformative vision for the future of oncology.<\/p>\n

\n

\"Keynote<\/a>
Keynote speech<\/span><\/p>\n<\/div>\n

“Over the past decade, Innovent has been at the forefront of China’s<\/span> biopharmaceutical evolution\u2014pioneering the PD-1 immunotherapy era and building China’s<\/span> leading oncology brand, with over 3 million cancer patients treated with our therapies,”\u00a0said Dr. Michael Yu<\/span>, Founder, Chairman of the Board and CEO of Innovent<\/b>.\u00a0“We are entering a new chapter focused on global innovation, powered by a robust pipeline and dual innovation of next-generation IO and next-generation ADC. Our recent presence at the 2025 ASCO with eight oral presentations highlights the strength and global competitiveness of our R&D. But this is only the beginning. With a clear vision to advance at least five pipeline assets into MRCT Phase 3 by 2030, we are committed to delivering innovative, high-quality, and accessible cancer treatments to patients worldwide.”<\/p>\n

Dual Innovation to Unlock the Future of Oncology: Next-gen IO + Next-gen ADC<\/b><\/p>\n

At the core of Innovent’s oncology strategy lies the dual engines of next-generation immunotherapy (IO) and next-generation antibody-drug conjugates (ADC), supported by deep insights in cancer biology and differentiated technology platforms.<\/p>\n

\n

\"Dual<\/a>
Dual Innovations of IO+ADC<\/span><\/p>\n<\/div>\n

“We are harnessing deep cancer biology insights, advanced antibody and protein engineering, and differentiated ADC linker-payload technologies to develop broader-spectrum, more potent, and less toxic therapies aimed at transforming the oncology treatment paradigm,” said Dr. Zhou Hui<\/span>, SVP of Innovent Oncology R&D<\/b>. “Our strategy is designed to target some of the toughest challenges in cancer care, including drug resistance, cold tumors, and improve the efficacy of current IO treatment, while bringing new hope to patients worldwide.”<\/p>\n

\n

\"Keynote<\/a>
Keynote speech<\/span><\/p>\n<\/div>\n

Global R&D Roadmap: a Clear, Stepwise Development Strategy\u00a0<\/b><\/p>\n

Innovent’s pipeline is guided by a rational, phased IO+ADC combination strategy designed to address tumor heterogeneity and immune escape, evolving through three stages:<\/p>\n